A Safety Evaluation of Empagliflozin for the Treatment of Type 2 Diabetes.

about

Effect of Empagliflozin on Tacrolimus-Induced Pancreas Islet Dysfunction and Renal Injury.

P2860

Q46380921-B5226E8A-54FA-4E9A-9CC4-B958363B9F32

P2860

A Safety Evaluation of Empagliflozin for the Treatment of Type 2 Diabetes.

Item

http://www.wikidata.org/entity/Q36960633

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

A Safety Evaluation of Empagliflozin for the Treatment of Type 2 Diabetes.

@en

type

Item

label

A Safety Evaluation of Empagliflozin for the Treatment of Type 2 Diabetes.

@en

prefLabel

A Safety Evaluation of Empagliflozin for the Treatment of Type 2 Diabetes.

@en

P1476

A Safety Evaluation of Empagliflozin for the Treatment of Type 2 Diabetes.

@en

P2093

Darren K McGuire

http://www.w3.org/2001/XMLSchema#string

Ian J Neeland

http://www.w3.org/2001/XMLSchema#string

Usman Salahuddin

http://www.w3.org/2001/XMLSchema#string

P2860

The risk of heart failure associated with the use of noninsulin blood glucose-lowering drugs: systematic review and meta-analysis of published observational studies

SGLT2 Inhibitors May Predispose to Ketoacidosis

Glucose control and vascular complications in veterans with type 2 diabetes

Pharmacokinetics, pharmacodynamics, safety and tolerability of 4 weeks' treatment with empagliflozin in Japanese patients with type 2 diabetes mellitus.

Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone.

Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality.

SGLT2 mediates glucose reabsorption in the early proximal tubule.

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.

Molecular physiology of sodium-glucose cotransporters.

Efficacy and safety of empagliflozin for type 2 diabetes: a systematic review and meta-analysis.

P304

393-402

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/14740338.2016.1135900

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-12-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26695551

http://www.w3.org/2001/XMLSchema#string

P921

type-2 diabetes

P932

4890479

http://www.w3.org/2001/XMLSchema#string

A Safety Evaluation of Empagliflozin for the Treatment of Type 2 Diabetes.

about

P2860

P2860

A Safety Evaluation of Empagliflozin for the Treatment of Type 2 Diabetes.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P921

P932